Sign Up to like & get
recommendations!
0
Published in 2018 at "Infection"
DOI: 10.1007/s15010-018-1168-7
Abstract: IntroductionHepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect. In vitro sofosbuvir inhibits HEV replication, but clinical…
read more here.
Keywords:
sofosbuvir ribavirin;
treatment;
acute hepatitis;
autochthonous acute ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Internal medicine"
DOI: 10.2169/internalmedicine.7337-21
Abstract: Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain…
read more here.
Keywords:
hepatitis;
sofosbuvir ribavirin;
inactive carriers;
infected hepatitis ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Antiviral Therapy"
DOI: 10.3851/imp3227
Abstract: Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit…
read more here.
Keywords:
sofosbuvir ribavirin;
heart transplant;
hepatitis;
hev ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Hepatitis Monthly"
DOI: 10.5812/hepatmon.45525
Abstract: Background: Documentation of the effectiveness of sofosbuvir and ribavirin with or without pegylated interferon alfa for hepatitis C virus Genotype 3 (HCV GT3) is limited in a real world setting. Objectives: The present study aimed…
read more here.
Keywords:
sofosbuvir ribavirin;
real world;
treatment;
interferon ... See more keywords